Plandai Biotech Stock Return On Equity
PLPL Stock | USD 0.0001 0.0001 50.00% |
Plandai Biotech fundamentals help investors to digest information that contributes to Plandai Biotech's financial success or failures. It also enables traders to predict the movement of Plandai Pink Sheet. The fundamental analysis module provides a way to measure Plandai Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Plandai Biotech pink sheet.
Plandai |
Plandai Biotech Company Return On Equity Analysis
Plandai Biotech's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition |
Based on the latest financial disclosure, Plandai Biotech has a Return On Equity of 0.0. This is 100.0% lower than that of the Biotechnology sector and about the same as Health Care (which currently averages 0.0) industry. The return on equity for all United States stocks is 100.0% lower than that of the firm.
Did you try this?
Run Odds Of Bankruptcy Now
Odds Of BankruptcyGet analysis of equity chance of financial distress in the next 2 years |
All Next | Launch Module |
Plandai Fundamentals
Return On Asset | -0.21 | |||
Operating Margin | (12.22) % | |||
Current Valuation | 236.87 K | |||
Shares Outstanding | 263.19 M | |||
Price To Earning | (0.32) X | |||
Price To Sales | 1.04 X | |||
Revenue | 411.99 K | |||
Gross Profit | (768.91 K) | |||
EBITDA | (2.1 M) | |||
Net Income | (4.01 M) | |||
Cash And Equivalents | 7.96 K | |||
Total Debt | 50.53 K | |||
Debt To Equity | 0.95 % | |||
Current Ratio | 0.01 X | |||
Book Value Per Share | (0.05) X | |||
Cash Flow From Operations | (1.1 M) | |||
Earnings Per Share | (0.03) X | |||
Number Of Employees | 250 | |||
Beta | -1.3 | |||
Market Capitalization | 276.35 K | |||
Total Asset | 6.82 M | |||
Retained Earnings | (39.32 M) | |||
Working Capital | (15.26 M) | |||
Current Asset | 176 K | |||
Current Liabilities | 15.44 M | |||
Z Score | -6.4 | |||
Net Asset | 6.82 M |
About Plandai Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Plandai Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Plandai Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Plandai Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Plandai Pink Sheet
Plandai Biotech financial ratios help investors to determine whether Plandai Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Plandai with respect to the benefits of owning Plandai Biotech security.